Biomarker & Intervention Discovery

Obesity (Severe / Morbid)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

FTO 166GIPR 187GLP1R 294LEPR 6MC4R 143NPY 11POMC 2UCP1 3
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BISANTRENE inhibits Mechanistic
ATENOLOL ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
AZATHIOPRINE ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
MERCAPTOPURINE ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ROXADUSTAT inhibits Mechanistic 9800.0 nM (IC50)
CHEMBL2338328 inhibits Mechanistic 84000.0 nM (IC50)
CHEMBL485023 inhibits Mechanistic 60000.0 nM (IC50)
CHEMBL2338327 inhibits Mechanistic 38000.0 nM (IC50)
CHEMBL426560 inhibits Mechanistic 2800.0 nM (IC50)
CHEMBL2338326 inhibits Mechanistic 43000.0 nM (IC50)
CHEMBL2338325 inhibits Mechanistic 96000.0 nM (IC50)
CHEMBL2030875 inhibits Mechanistic 92000.0 nM (IC50)
CHEMBL1256568 inhibits Mechanistic 15000.0 nM (IC50)
CHEMBL2338323 inhibits Mechanistic 18000.0 nM (IC50)
CHEMBL2338322 inhibits Mechanistic 23000.0 nM (IC50)
CHEMBL1230640 inhibits Mechanistic 3300.0 nM (IC50)
BROMAMINIC ACID inhibits Mechanistic 11000.0 nM (IC50)
CHEMBL2338321 inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL316034 inhibits Mechanistic 8300.0 nM (IC50)
N-OXALYLGLYCINE inhibits Mechanistic 44000.0 nM (IC50)
CHEMBL3613953 inhibits Mechanistic 13000.0 nM (Kd)
CHEMBL4563024 inhibits Mechanistic 700.0 nM (IC50)
CHEMBL4559749 inhibits Mechanistic 7600.0 nM (IC50)
CHEMBL4470475 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4521076 inhibits Mechanistic 4600.0 nM (IC50)
CHEMBL4576909 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4435677 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4517902 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4471543 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4572939 inhibits Mechanistic 60.0 nM (IC50)
CHEMBL4563561 inhibits Mechanistic 1140.0 nM (IC50)
CHEMBL4460597 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4474254 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4453402 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL4567838 inhibits Mechanistic 1600.0 nM (IC50)
CHEMBL4532629 inhibits Mechanistic 400.0 nM (IC50)

Showing top 40 of 166 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TIRZEPATIDE activates Mechanistic 0.03 nM (EC50)
COMPOUND 15A [PMID: 36642961] inhibits Mechanistic
OLANZAPINE ? unclear Mechanistic
CHEMBL198387 inhibits Mechanistic 430.0 nM (IC50)
CHEMBL234087 inhibits Mechanistic 132.0 nM (IC50)
CHEMBL411832 inhibits Mechanistic 117.0 nM (IC50)
CHEMBL395759 inhibits Mechanistic 217.0 nM (IC50)
CHEMBL411831 inhibits Mechanistic 178.0 nM (IC50)
CHEMBL232241 inhibits Mechanistic 171.0 nM (IC50)
CHEMBL232239 inhibits Mechanistic 435.0 nM (IC50)
CHEMBL398180 inhibits Mechanistic 603.0 nM (IC50)
CHEMBL396215 inhibits Mechanistic 296.0 nM (IC50)
CHEMBL407028 inhibits Mechanistic 4256.0 nM (IC50)
CHEMBL411833 inhibits Mechanistic 2023.0 nM (IC50)
CHEMBL232448 inhibits Mechanistic 3525.0 nM (IC50)
CHEMBL430163 inhibits Mechanistic 1279.0 nM (IC50)
CHEMBL232037 inhibits Mechanistic 610.0 nM (IC50)
CHEMBL232242 inhibits Mechanistic 118.0 nM (IC50)
CHEMBL232224 inhibits Mechanistic 286.0 nM (IC50)
CHEMBL198736 inhibits Mechanistic 28.3 nM (IC50)
CHEMBL452451 inhibits Mechanistic 497.0 nM (IC50)
CHEMBL528775 inhibits Mechanistic 411.0 nM (IC50)
CHEMBL447684 inhibits Mechanistic 277.0 nM (IC50)
CHEMBL455214 inhibits Mechanistic 83.0 nM (IC50)
CHEMBL487668 inhibits Mechanistic 93.0 nM (IC50)
CHEMBL447742 inhibits Mechanistic 74.0 nM (IC50)
CHEMBL504245 inhibits Mechanistic 198.0 nM (IC50)
CHEMBL453457 inhibits Mechanistic 12.0 nM (IC50)
CHEMBL520893 inhibits Mechanistic 406.0 nM (IC50)
CHEMBL487662 inhibits Mechanistic 1392.0 nM (IC50)
CHEMBL486651 inhibits Mechanistic 98.0 nM (IC50)
CHEMBL456738 inhibits Mechanistic 145.0 nM (IC50)
CHEMBL509710 inhibits Mechanistic 279.0 nM (IC50)
CHEMBL445532 inhibits Mechanistic 380.0 nM (IC50)
CHEMBL452311 inhibits Mechanistic 216.0 nM (IC50)
CHEMBL452067 inhibits Mechanistic 220.0 nM (IC50)
CHEMBL452310 inhibits Mechanistic 3020.0 nM (IC50)
CHEMBL504156 inhibits Mechanistic 373.0 nM (IC50)
CHEMBL499160 inhibits Mechanistic 87.0 nM (IC50)
CHEMBL375167 inhibits Mechanistic 93.0 nM (IC50)

Showing top 40 of 187 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL:CHEMBL607309 ? unclear Mechanistic
CHEMBL:CHEMBL585444 ? unclear Mechanistic
CHEMBL:CHEMBL1327172 ? unclear Mechanistic
CHEMBL:CHEMBL1224483 ? unclear Mechanistic
CGP13501 ? unclear Mechanistic
CHEMBL:CHEMBL580340 ? unclear Mechanistic
EFPEGLENATIDE activates Mechanistic
LIRAGLUTIDE ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL597251 ? unclear Mechanistic
ANGUSTIBALIN ? unclear Mechanistic
DULAGLUTIDE activates Mechanistic
EXENATIDE activates Mechanistic 0.66 nM (IC50)
MOFEBUTAZONE ? unclear Mechanistic
CHEMBL:CHEMBL532412 ? unclear Mechanistic
NORTRIPTYLINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL533602 ? unclear Mechanistic
PEGSEBRENATIDE activates Mechanistic
OLANZAPINE ? unclear Mechanistic
CHEMBL:CHEMBL317115 ? unclear Mechanistic
CHEMBL:CHEMBL1549738 ? unclear Mechanistic
CYCLOASPEPTIDE A ? unclear Mechanistic
SCOULERINE ? unclear Mechanistic
KEPONE ? unclear Mechanistic
PEGAPAMODUTIDE activates Mechanistic
CHEMBL:CHEMBL603154 ? unclear Mechanistic
ETOPOSIDE ? unclear Mechanistic
CHEMBL:CHEMBL405914 ? unclear Mechanistic
CHEMBL:CHEMBL1308346 ? unclear Mechanistic
FIDUXOSIN HYDROCHLORIDE ? unclear Mechanistic
CLOZAPINE ? unclear Mechanistic
CHEMBL:CHEMBL578515 ? unclear Mechanistic
CHEMBL:CHEMBL1439833 ? unclear Mechanistic
CHEMBL:CHEMBL601351 ? unclear Mechanistic
CHEMBL:CHEMBL580727 ? unclear Mechanistic
AMORFRUTIN A ? unclear Mechanistic
PROPIONYLPROMAZINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL588038 ? unclear Mechanistic
CHEMBL:CHEMBL1420370 ? unclear Mechanistic
CHEMBL:CHEMBL580207 ? unclear Mechanistic

Showing top 40 of 294 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MIBAVADEMAB activates Mechanistic
SIMVASTATIN ? unclear Mechanistic
VALPROIC ACID ? unclear Mechanistic
METRELEPTIN activates Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
SETMELANOTIDE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SETMELANOTIDE ACETATE activates Mechanistic
AMISULPRIDE ? unclear Mechanistic
PF-00446687 activates Mechanistic
CHLORHEXIDINE GLUCONATE ? unclear Mechanistic
OLANZAPINE ? unclear Mechanistic
QUETIAPINE FUMARATE ? unclear Mechanistic
PMX53 ? unclear Mechanistic
AMLINTIDE ? unclear Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
SETMELANOTIDE activates Mechanistic
ZIPRASIDONE ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic
PALIPERIDONE ? unclear Mechanistic
BREMELANOTIDE ACETATE activates Mechanistic
ARIPIPRAZOLE LAUROXIL ? unclear Mechanistic
METHYLNALTREXONE ? unclear Mechanistic
BREMELANOTIDE activates Mechanistic
CHEMBL:CHEMBL578944 ? unclear Mechanistic
TREBANANIB ? unclear Mechanistic
CLOZAPINE ? unclear Mechanistic
CHEMBL415341 activates Mechanistic 9.0 nM (EC50)
CHEMBL437822 activates Mechanistic 7.0 nM (EC50)
CHEMBL24892 activates Mechanistic 0.9 nM (EC50)
CHEMBL438286 activates Mechanistic 15.0 nM (EC50)
CHEMBL412174 activates Mechanistic 10.0 nM (EC50)
CHEMBL264337 activates Mechanistic 7.0 nM (EC50)
CHEMBL439361 activates Mechanistic 35.0 nM (EC50)
CHEMBL2371902 activates Mechanistic 3.0 nM (EC50)
CHEMBL2371888 activates Mechanistic 25.0 nM (EC50)
CHEMBL3037885 activates Mechanistic 0.3 nM (EC50)
CHEMBL410148 activates Mechanistic 2.0 nM (EC50)
CHEMBL2371880 activates Mechanistic 5.0 nM (EC50)
CHEMBL2371903 activates Mechanistic 2.0 nM (EC50)
CHEMBL409786 activates Mechanistic 6.0 nM (EC50)
CHEMBL216474 activates Mechanistic 37.0 nM (EC50)
CHEMBL406636 activates Mechanistic 176.0 nM (EC50)
CHEMBL2371913 activates Mechanistic 65.0 nM (EC50)
CHEMBL262437 activates Mechanistic 33.0 nM (EC50)
CHEMBL386871 activates Mechanistic 45.0 nM (EC50)
CHEMBL384036 activates Mechanistic 105.0 nM (EC50)

Showing top 40 of 143 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
HALOPERIDOL DECANOATE ? unclear Mechanistic
K-252A ? unclear Mechanistic
ANTIHYPERTENSIVE AGENT ? unclear Mechanistic
ENDOTHELIN RECEPTOR ANTAGONIST ? unclear Mechanistic
ROSIGLITAZONE ? unclear Mechanistic
ESTRADIOL 3-BENZOATE ? unclear Mechanistic
BROMOCRIPTINE ? unclear Mechanistic
FREUND'S ADJUVANT ? unclear Mechanistic
VACCINE ? unclear Mechanistic
IMMUNOTOXIN ? unclear Mechanistic
ETHER ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERMEDINE ? unclear Mechanistic
SETMELANOTIDE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
STREPTOZOCIN ? unclear Mechanistic
METYROSINE ? unclear Mechanistic

Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT02310178 Phase: NA Started: 2012-05-21

The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.

NCT01047735 Phase: NA Started: 2009-09-01

This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in Type 2 diabetes mellitus (T2DM) in moderately obese patients. T2DM is ...

NCT06133413 Phase: NA Started: 2025-06-26

In this research, we hypothesize that post-operative monitoring implemented with a connected scale after the 1st year (weight nadir period) post obesity surgery (i.e. sleeve and RYGB) would reduce the percentage of patients with excessive weight regain (\>10% regain of lost weight) by improving the ...

NCT07590219 Phase: PHASE4 Started: 2024-03-30

This randomized controlled trial evaluates the efficacy, safety, metabolic, and cardiovascular effects of liraglutide in children aged 6 to 12 years with severe obesity. Participants are randomized to receive liraglutide plus lifestyle intervention or lifestyle intervention alone for 6 months. In ad...

NCT07520942 Phase: NA Started: 2025-10-25

This randomized controlled trial evaluates the effectiveness of adding TECAR therapy or extracorporeal shock wave therapy (ESWT) to complex decongestive therapy (CDT) in the treatment of bilateral lower-limb lymphedema in severely obese patients. Forty-five female participants were randomly assigned...

NCT06548100 Phase: PHASE3 Started: 2024-12-16

This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switc...

NCT03538210 Phase: N/A Started: 2018-02-16

Obesity prevalence rapidly increased in the past decades in French population with multiple health consequences responsible for excess mortality. In the same period of time, the number of bariatric procedures have developed exponentially. Despite its great efficacy on weight loss but also on resolut...

NCT06309563 Phase: NA Started: 2023-08-30

The effectiveness of low-protein diets supplemented with essential aminoacid (EAA) formulas in genetic disorders of amino acid (AA) catabolism, such as maple syrup urine disease (MSUD), is widely recognized (Blackburn PR et al. 2017). The main aim of the present study is to evaluate a difference in ...

NCT04915014 Phase: NA Started: 2021-07-23

Obesity is a major public health problem worldwide. Bariatric surgery has proved to be the most effective treatment of morbid obesity in terms of weight reduction and remission of co-morbid conditions during long-term follow-up. Sleeve Gastrectomy (SG) has become the most performed intervention eith...

NCT06477120 Phase: NA Started: 2024-09-09

In the United States, a body mass index (BMI) of at least 35.0 kg/m2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, b...

NCT07335549 Phase: N/A Started: 2025-07-01

Obesity is a multifactorial disease which has become a public health problem with increasing frequency, especially in recent years. Obesity causes many health problems with its negative effects on organs, systems, and psychosocial status. It is a serious risk factor for many diseases and also causes...

NCT07004556 Phase: N/A Started: 2025-07-01

Obesity is a major global health concern with a rising prevalence and numerous associated comorbidities. For the treatment of severe obesity, bariatric surgery stands as the most effective procedure. Bariatric and metabolic surgical procedures are applied even in the absence of comorbidities, partic...

NCT07058155 Phase: PHASE4 Started: 2025-12-17

Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. C...

NCT07280845 Phase: N/A Started: 2012-01-01

The main questions to answer are: * Weight outcomes in weight strata over time? * What was the proportion of patients reaching sufficient weight outcome in different weight strata? * To what extent are co-morbid conditions improved or put in remission? * What is the risk of experience a complicatio...

NCT04626570 Phase: NA Started: 2021-01-20

Morbid or severe obesity is a chronic pathology of multifactorial etiology that affects 4.3% of the French population. In these patients, eating disorders are frequent and must be managed as they are considered risk factors with poorer weight prognosis and lower quality of life. Some authors have p...


Agents Found By Disease-Level Search

Searched directly from “Obesity (Severe / Morbid)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.